Carlota Dobaño

Oct 24, 2024 | nature.com | Robert Mitchell |Akshayata Naidu |Pedro Aide |Ruth Aguilar |Claudia A Daubenberger |Carlota Dobaño | +1 more

AbstractRTS,S/AS01E, the first approved malaria vaccine, demonstrated moderate efficacy during the phase 3 pediatric trial. We previously investigated cell-mediated immune (CMI) responses following the primary 3-dose immunization and now report responses to the booster dose given 18 months later.